Exelixis
✦ Quant Fair Value how this is computed
- Implied fair-value range of 38.74-116.81, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is -16.9% below the average-multiple fair value of 77.77.
Valuation each multiple against its own 5-year range
Vs. peers Biotechnology
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Exelixis (EXEL) | 15.77B | 19.35 | 8.60 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 130.58B | 33.14 | 6.25 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 95.24B | 20.35 | 2.84 | 0.40% |
| Moderna (MRNA) | 78.90B | -27.70 | 11.54 | 0.00% |
| argenx SE (ARGX) | 58.21B | 32.06 | 6.92 | 0.00% |
| BeiGene (ONC) | 44.66B | 49.74 | 7.67 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 2.3% below Morningstar's fair value estimate.
Fair value
Exelixis Inc earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a price consistent with our quantitative fair value estimate, which has a high uncertainty rating.
The firm's balance sheet bolsters our valuation estimate. Low leverage mitigates financial risk, potentially boosting a firm's value. Reflecting the firm's leverage is its debt to EBITDA ratio of 0.2, which falls in the bottom 10% compared with peers globally. Without much debt relative to assets, this company should exhibit high resilience should the global economy weaken; if not, the company could raise debt and invest in the business or return capital to shareholders. This benefit contributes to our balanced fair value estimate.
Conversely, the company's unfavorable dividend structure is potentially concerning. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. The firm's forward dividend yield of 0%, for example, falls in the bottom 30% compared with peers globally. This could imply a planned dividend cut or relatively high share price, which further promotes our neutral price/fair value ratio.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is fairly-valued, this outperformance had a negative impact on our valuation estimate.
Economic moat
The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.
By Quantitative Equity Report
Quote time 2026-11-20 20:02:41 · For reference only, not investment advice and not tailored to your situation.
Exelixis discussion 0 comments